In a study investigating the use of magic mushrooms in Canada, nearly 80% of the respondents expressed their conviction that psilocybin, the active compound in magic mushrooms, should be medically available for patients who are suffering. Moreover, about two-thirds of the Canadian respondents from the same study concurred that psilocybin should be legally accessible for those who need it.
Besides advocating for easier access to the substance, a noteworthy 84.8 percent of the respondents are of the opinion that the expenses for such therapies should be covered by the public health system. A significant portion of Canadians view psilocybin as a valid choice, particularly for alleviating end-of-life distress.
[toc]
Key Takeaways:
- Residents of Québec, Ontario, Alberta, and British Columbia recognize psilocybin as a potential medical solution for managing end-of-life existential distress.
- Magic mushrooms are perceived as safe for treating existential distress.
- Participants in two double-blind trials reported immediate and sustained benefits, with effects enduring six months or more.
Deciphering Existential Distress
Existential distress, closely related to existential suffering, spiritual distress, and demoralization, arises when individuals grapple with their mortality. Patients may endure feelings of helplessness, isolation, anxiety, and a loss of purpose and meaning. This form of distress is particularly prevalent among patients with life-threatening illnesses, potentially leading to thoughts of hastening death or contemplating suicide.
Usually, individuals dealing with terminal illnesses or significant life changes are the ones most likely to experience this form of distress. It can severely impact their mental health and overall quality of life.
Existential therapy aims to tackle issues such as anxiety, depression, grief, loneliness, apathy, despair, identity confusion, and feelings of purposelessness and existential fear. This therapy may involve multiple sessions and may not prove effective for everyone.
The uncertainty regarding the effectiveness of such therapy is a major reason why many individuals seek alternative treatments.
Health Canada’s Stance on Psilocybin as a Therapeutic Option
In the last two decades, preliminary clinical trials have highlighted the potential advantages of psychedelic substances for managing complex mental disorders. Among these, psilocybin has demonstrated its ability to provide fast and long-lasting relief from existential distress in patients facing end-of-life situations.
Recognizing the potential efficacy of these proposed hallucinogenic mushrooms, especially when conventional treatments are inadequate, Health Canada revised the Special Access Program in 2022. This revision permits healthcare providers to apply for controlled substances on behalf of their patients.
Canadian Endorsement of Psilocybin Access
A research piece published in the Palliative Care Journal examines public attitudes towards psilocybin-assisted therapy for end-of-life care. The study’s data includes:
| Methodology | Survey involving 2,800 Canadians from Québec, Ontario, Alberta, and British Columbia. 19% of the participants had previously used psilocybin (15% in Québec, 26% in British Columbia). |
| Findings | 79.3% regard psilocybin-assisted therapy as a legitimate medical option for treating end-of-life existential distress. 63.3% believe psilocybin should be integrated into medical treatment. 84.8% favor the delivery of this therapy by the public health system. 44.2% think healthcare professionals should administer the substance without Health Canada’s supervision. |
The findings align with surveys carried out in Canada, England, and Australia. The researchers highlighted the uniqueness of their study, which focuses on the use of psychoactive substances for managing existential distress in end-of-life situations.
Reasons for Canadian Endorsement of Psilocybin Use
An increasing number of Canadians are supporting the use of psilocybin as a treatment option, primarily because of the compelling findings from reputable research institutions. Another motivating factor is the perceived safety of psilocybin mushrooms for reducing existential distress. No severe adverse health effects, such as multi-organ failure, have been reported in subjects across various studies.
| Study | Approach | Outcomes |
| Johns Hopkins Study | 51 patients were administered a high dose of psilocybin and a low dose as an active placebo control | Immediate and sustained The benefits of this therapy can last up to six months or more. Its effectiveness is largely derived from mystical experiences that include a sense of oneness and deep emotional revelations. |
| Trial at New York University | 29 patients were randomly chosen to either receive psilocybin or the active placebo niacin | The results were in line with the Johns Hopkins study. Participants who were administered psilocybin reported psychological relief along with an enhanced perspective on life and death. |
| BMC Palliative Care | 19 participants, including 7 doctors, 4 nurses, 4 chaplains, 3 social workers, and a psychologist, were interviewed. The aim of the study was to understand the perspectives of palliative care professionals on existential distress and their views on psychedelic therapy as a potential treatment. | Palliative care practitioners reported that psychedelic-assisted therapy (PAT) could potentially alleviate existential distress. |
Patient Experiences
Scientific research isn’t the only evidence supporting the effectiveness of psilocybin. Numerous patient stories highlight its potential to improve mental health and enhance the overall quality of life.
The Journey of Yokoi
Mio Yokoi, a patient with terminal stage 4 pancreatic cancer, shares a transformative experience during her assisted therapy. She envisions herself on a raft, surrounded by nature and accompanied by fantasy creatures. This vision instills in her a profound sense of the universe’s interconnectedness and support, imparting immense peace and affirmation.
Despite availing traditional mental health services, Yokoi continued to experience severe anxiety and distress post-diagnosis. Psilocybin therapy facilitated a reconnection with her body and provided a tangible sense of love and support, significantly improving her emotional and mental health.
The Story of Chrissy
Chrissy, a woman in her 50s, was diagnosed with stage 4 breast cancer, which had metastasized to her lungs. She worked full-time as an administrative supervisor in healthcare when the study was conducted and identifies herself as an atheist. She was diagnosed with Generalized Anxiety Disorder during her screening.
Following the therapy, Chrissy reported significant reductions in anxiety, depression, fear of death, hopelessness, and demoralization. When asked about any changes in her spiritual or religious beliefs post-therapy, she stated that the experiences had brought a sense of purpose and authenticity to her beliefs.
Brenda’s Journey
In the course of her therapy, Brenda experienced death twice. These experiences led her to perceive death not as a fear, but as a beautiful aspect of life’s cycle. She credited her journey of healing from childhood trauma to the study. Her data reflected this profound change.
She reported reduced anxiety and fear of death, along with an increase in spirituality.
Availability of Magic Mushroom Products in Canada
At present, there may be limitations on the accessibility of psilocybin capsules and other products designed to alleviate existential distress or other psychological issues. However, reliable online dispensaries can serve as an excellent resource for obtaining these products when needed.
| Attribute | Brazilian Psilocybe Cubensis | Cambodian Psilocybe Cubensis | Melmac Psilocybe Cubensis |
| Origin | Native to Brazil and some neighboring South American countries. | Discovered in Cambodia, near the Angkor Wat Temple. | Related to the popular Penis Envy mushrooms from the 1970s. |
| Potency | Moderately potent; suitable for beginners. | Moderate potency; perfect for new users. | Highly potent; advisable for individuals with intermediate to advanced experience. |
| Effects | Produces a mental buzz, minor disorientation, enhances color perception, creates euphoria, induces spiritual experiences, enhances creativity, and improves focus. | Triggers an energizing, enduring high, slight visual changes, boosts creativity, elicits euphoria, provides a gentle physical high, results in fractal images, and induces feelings of happiness. | Generates profound shamanic experiences, vision quests, intense mystical experiences, increases creativity, focus, social awareness, and enhances mood. |
Ease End-of-life Discomfort with Psilocybin Products
Existential or end-of-life distress can exert immense pressure on patients nearing the end of their lives. Conventional treatments for this distress may not always be effective, leading to a growing acceptance in Canada for more accessible magic mushrooms in public healthcare. This increased public interest could
We urge regulatory authorities to recognize the therapeutic potential of magic mushrooms. For your psychedelic needs, obtain your shroom delivery from Shroom Delivery Canada.
Frequently Asked Questions
What should patients expect from Psilocybin-Assisted Therapy?
The experience of Psychedelic-assisted therapy (PAT) can be highly individual, and following careful protocols is crucial for a positive outcome. Comprehensive screening and mental readiness are prerequisites before the substance intake.
- Preparation Phase: Prior to the session, patients undergo a detailed assessment. The therapist aligns with the patient’s goals and expectations to set the session’s intent. The potential effects of the process and the session’s expectations are communicated to the patient.
- The Therapeutic Session: In a serene, distraction-less environment, patients receive a controlled dose of the substance. The therapist furnishes constant support and direction throughout the session.
- Post-session Integration Therapy: This therapy helps patients comprehend and assimilate their experiences. Follow-up sessions provide persistent support and counseling to reinforce the insights and transformations obtained during therapy.
How does psilocybin affect the brains of distressed patients?
Psilocybin interacts with the brain by attaching to serotonin receptors, particularly the 5-HT2A receptor. This bonding can cause alterations in perception, mood, and thought process, leading to profound changes in awareness, emotional insights, and new viewpoints.
Is psilocybin therapy available to everyone?
Psilocybin therapy isn’t universally fit. Individuals with specific mental health conditions or existential distress are meticulously screened to exclude those with a past record of psychosis.
Further Reading:
